A Phase 2, Parallel-Group, Double-Blind 4-arm Study to Investigate the Effects of Treatment With LY3549492 Tablets Compared With Placebo in an Obese or Overweight Population With Type-2 Diabetes (T2D)
Latest Information Update: 27 Jun 2025
At a glance
- Drugs LY 3549492 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
Most Recent Events
- 27 Jun 2025 New trial record